Sage Therapeutics, Inc. – NASDAQ:SAGE
Sage Therapeutics stock price today
$8.69
+3.14
+56.86%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Sage Therapeutics stock price monthly change
-52.89%
month
Sage Therapeutics stock price quarterly change
-52.89%
quarter
Sage Therapeutics stock price yearly change
-75.11%
year
Sage Therapeutics key metrics
Market Cap | 334.00M |
Enterprise value | 2.42B |
P/E | -4.91 |
EV/Sales | 315.39 |
EV/EBITDA | -4.68 |
Price/Sales | 334.98 |
Price/Book | 2.05 |
PEG ratio | 0.32 |
EPS | -8.4 |
Revenue | 91.06M |
EBITDA | -473.61M |
Income | -503.14M |
Revenue Q/Q | 139.89% |
Revenue Y/Y | 868.86% |
Profit margin | -6930.97% |
Oper. margin | -7115.75% |
Gross margin | 89.42% |
EBIT margin | -7115.75% |
EBITDA margin | -520.09% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSage Therapeutics stock price history
Sage Therapeutics stock forecast
Sage Therapeutics financial statements
Average Price Target
$12.86
Potential upside: 47.95%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 2.47M | -160.32M | -6480.4% |
|---|---|---|---|
| Sep 2023 | 2.71M | -201.63M | -7423.78% |
| Dec 2023 | 77.97M | -32.70M | -41.95% |
| Mar 2024 | 7.90M | -108.48M | -1372.85% |
| Jun 2023 | 1082288000 | 97.91M | 9.05% |
|---|---|---|---|
| Sep 2023 | 949663000 | 133.00M | 14.01% |
| Dec 2023 | 882277000 | 82.74M | 9.38% |
| Mar 2024 | 767600000 | 61.79M | 8.05% |
| Jun 2023 | -131.51M | 45.59M | 847K |
|---|---|---|---|
| Sep 2023 | -135.86M | 160.39M | 2.77M |
| Dec 2023 | -119.51M | 42.06M | -262K |
| Mar 2024 | -37.83M | 139.43M | 1.55M |
Sage Therapeutics alternative data
| Aug 2023 | 689 |
|---|---|
| Sep 2023 | 689 |
| Oct 2023 | 689 |
| Nov 2023 | 689 |
| Dec 2023 | 689 |
| Jan 2024 | 689 |
| Feb 2024 | 689 |
| Mar 2024 | 487 |
| Apr 2024 | 487 |
| May 2024 | 487 |
| Jun 2024 | 487 |
| Jul 2024 | 487 |
Sage Therapeutics other data
84.24%
-0.50%
of SAGE is owned by hedge funds
193
-9
49.42M
-422.30K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2022 | 14500 | 0 |
| Feb 2023 | 0 | 11643 |
| May 2023 | 1000 | 0 |
| Aug 2023 | 2000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | IGUCHI KIMI officer: CFO & Tr.. | Common Stock | 1,642 | $1.36 | $2,233 | ||
Option | IGUCHI KIMI officer: CFO & Tr.. | Stock Option (Right to Buy) | 1,642 | $1.36 | $2,233 | ||
Purchase | BARRETT ELIZABETH director | Common Stock | 2,000 | $18.64 | $37,278 | ||
Purchase | BARRETT ELIZABETH director | Common Stock | 1,000 | $50.5 | $50,500 | ||
Option | IGUCHI KIMI officer: CFO & Tr.. | Stock Option (Right to Buy) | 3,000 | $1.36 | $4,080 | ||
Option | IGUCHI KIMI officer: CFO & Tr.. | Common Stock | 3,000 | $1.36 | $4,080 | ||
Option | IGUCHI KIMI officer: CFO & Tr.. | Stock Option (Right to Buy) | 250 | $1.36 | $340 | ||
Option | IGUCHI KIMI officer: CFO & Tr.. | Common Stock | 250 | $1.36 | $340 | ||
Option | IGUCHI KIMI officer: CFO & Tr.. | Stock Option (Right to Buy) | 750 | $1.36 | $1,020 | ||
Option | IGUCHI KIMI officer: CFO & Tr.. | Common Stock | 750 | $1.36 | $1,020 |
| Patent |
|---|
Grant Filling date: 26 Apr 2019 Issue date: 30 Aug 2022 |
Grant Filling date: 15 Jul 2020 Issue date: 9 Aug 2022 |
Grant Filling date: 11 Jul 2017 Issue date: 26 Jul 2022 |
Application Filling date: 15 Mar 2022 Issue date: 14 Jul 2022 |
Application Filling date: 15 Mar 2022 Issue date: 7 Jul 2022 |
Application Filling date: 6 Aug 2021 Issue date: 2 Jun 2022 |
Grant Filling date: 10 Jul 2019 Issue date: 31 May 2022 |
Application Filling date: 3 Feb 2022 Issue date: 19 May 2022 |
Application Filling date: 23 Dec 2021 Issue date: 14 Apr 2022 |
Application Filling date: 14 Sep 2018 Issue date: 14 Apr 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 25 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 14 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q1 2023 2 May 2023 | Q1 2023 Earnings Call Transcript |
Biogen: LAQEMBI's $10 Billion Potential
Sage Therapeutics: Several Neuropsychiatric Disorder Data Readouts In 2024
Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play
Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity
Sage Therapeutics: Zuranolone August Approval Likely, Opportunity Uncertain
Sage Therapeutics: Mid-2023 Data Readout And Possible FDA Approval Make This A Must Watch
Buy Biogen For Runups To Imminent Regulatory Decisions
Biogen Should Resume Strong Growth With Zuranolone Approval
Sage Therapeutics Looking To FDA Approval Of Zuranolone
-
What's the price of Sage Therapeutics stock today?
One share of Sage Therapeutics stock can currently be purchased for approximately $8.69.
-
When is Sage Therapeutics's next earnings date?
Unfortunately, Sage Therapeutics's (SAGE) next earnings date is currently unknown.
-
Does Sage Therapeutics pay dividends?
No, Sage Therapeutics does not pay dividends.
-
How much money does Sage Therapeutics make?
Sage Therapeutics has a market capitalization of 334.00M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1024.84% to 86.46M US dollars.
-
What is Sage Therapeutics's stock symbol?
Sage Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SAGE".
-
What is Sage Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sage Therapeutics?
Shares of Sage Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sage Therapeutics's key executives?
Sage Therapeutics's management team includes the following people:
- Dr. Jeffrey M. Jonas Chief Innovation Officer, Chair of the Science & Technology Forum and Director(age: 72, pay: $1,200,000)
- Ms. Anne Marie Cook Senior Vice President, Gen. Counsel & Sec.(age: 63, pay: $668,150)
- Dr. Albert J. Robichaud Ph.D. Chief Scientific Officer(age: 64, pay: $657,130)
- Ms. Kimi E. Iguchi Chief Financial Officer & Treasurer(age: 63, pay: $645,260)
- Mr. Barry E. Greene Pres, Chief Executive Officer & Director(age: 62, pay: $54,190)
-
How many employees does Sage Therapeutics have?
As Jul 2024, Sage Therapeutics employs 487 workers.
-
When Sage Therapeutics went public?
Sage Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 18 Jul 2014.
-
What is Sage Therapeutics's official website?
The official website for Sage Therapeutics is sagerx.com.
-
Where are Sage Therapeutics's headquarters?
Sage Therapeutics is headquartered at 215 First Street, Cambridge, MA.
-
How can i contact Sage Therapeutics?
Sage Therapeutics's mailing address is 215 First Street, Cambridge, MA and company can be reached via phone at +61 72998380.
-
What is Sage Therapeutics stock forecast & price target?
Based on 7 Wall Street analysts` predicted price targets for Sage Therapeutics in the last 12 months, the avarage price target is $12.86. The average price target represents a 47.95% change from the last price of $8.69.
Sage Therapeutics company profile:
Sage Therapeutics, Inc.
sagerx.comExchange:
NASDAQ
Full time employees:
487
Industry:
Biotechnology
Sector:
Healthcare
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
215 First Street
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001597553
ISIN: US78667J1088
CUSIP: 78667J108
